PRF Serum Fraction via Negatively Charged Surface Activation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for preparing platelet-rich fibrin (PRF) often involve anticoagulants and complex processing techniques, which can affect the quality and efficacy of the final product, and there is a need for improved materials to facilitate bone regeneration, especially in cases of bone ischemia.

Innovation Solution

A method for preparing an isolated serum fraction of PRF without anticoagulants, involving the spontaneous clotting of platelet-rich plasma (PRP) followed by separation of the coagel to isolate the activated platelet releasate, which is enriched in growth factors and cytokines, using a closed system and negatively charged surfaces to accelerate coagulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If anticoagulants are used in PRP preparation, then platelet concentration is maintained, but platelet activation and growth factor release are inhibited

Engineering Contradiction:
Improveplatelet concentrationVSAvoidgrowth factor release efficacy
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent applies preliminary action by pre-coating the centrifation tube surface with negatively charged material (such as silane-treated glass or plasma-treated polymer) before blood introduction. This pre-prepared surface immediately activates platelets upon contact during centrifugation, ensuring growth factor release occurs despite the presence of anticoagulants in the PRP preparation process.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent introduces an intermediary element - the negatively charged surface coating - that mediates between the anticoagulated PRP and the desired platelet activation. This surface acts as a catalyst that triggers platelet activation and growth factor release without requiring removal of anticoagulants, thus resolving the contradiction between maintaining platelet concentration and achieving reliable growth factor release.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If complex processing techniques are used to prepare PRF, then product quality is improved, but manufacturing complexity and processing time increase

Engineering Contradiction:
Improveproduct qualityVSAvoidprocessing technique complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-coating the centrifation tube surface with negatively charged material before blood introduction. This pre-prepared surface ensures that platelet activation occurs automatically during the standard centrifugation process, eliminating the need for additional activation steps and simplifying the overall workflow while maintaining high product quality.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent implements self-service by designing a system where the centrifugation process itself activates platelets through the pre-coated surface. The PRF preparation becomes self-activating during centrifugation, removing the need for external activation agents or additional processing steps, thus reducing manufacturing complexity while preserving product quality.

Inventive Principle:
Principle #25Self-service

3Ease of operation

If open system processing is used, then ease of operation is improved, but contamination risk increases

Engineering Contradiction:
Improveprocessing simplicityVSAvoidcontamination risk
Core Design Contradiction:
Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by utilizing a closed-system centrifation tube with integrated surface coating technology. The closed system prevents contamination while the pre-coated surface ensures platelet activation occurs within the sealed environment, maintaining both ease of operation and contamination control.

Inventive Principle:
Principle #30Flexible shells and thin films

Solution Approach 2:

The patent creates a controlled, sterile environment within the closed centrifation system. The inert, pre-treated surface coating provides a contamination-free zone that activates platelets without exposing the sample to external contaminants, thus maintaining operational simplicity while eliminating contamination risks.

Inventive Principle:
Principle #39Inert atmosphere (Inert environment)

4Device complexity

If standard centrifugation is used without surface activation, then device simplicity is maintained, but platelet activation efficiency is reduced

Engineering Contradiction:
Improvecentrifugation system simplicityVSAvoidplatelet activation efficiency
Core Design Contradiction:
Device complexityVSProductivity

Solution Approach 1:

The patent applies local quality by modifying only the internal surface of the centrifation tube with negatively charged coating, while keeping the centrifugation device itself simple and unchanged. This localized modification at the blood-contact surface provides high platelet activation efficiency without complicating the overall centrifugation system design.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent changes the surface charge parameter of the centrifation tube from neutral to negatively charged through coating treatment. This parameter change enables efficient platelet activation during standard centrifugation, significantly improving activation efficiency while maintaining device simplicity as no mechanical or operational changes to the centrifuge are required.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method produces a serum fraction with a high concentration of activated platelet releasate and growth factors, enhancing bone regeneration and tissue repair, particularly in conditions like bone ischemia, with improved stability and reduced contamination.

Implementation Method 1

using a closed system and negatively charged surfaces to accelerate coagulation

Methodology Applied
Scientific EffectCoagulation: Coagulation

Implementation Method 2

separating the coagel to isolate the serum fraction which comprises an activated platelet releasate

Methodology Applied
Scientific EffectCentrifugal separation: Centrifugal Separation

Data Source

PatentEP2956150B1Serum fraction of platelet-rich fibrin
Publication Date: 2021.08.11 LACERTA TECHNOLOGY LTD
  • EP2956150B1 patent drawingFigure 1
  • EP2956150B1 patent drawingFigure 2A~2D
  • EP2956150B1 patent drawingFigure 3A~3B

AI summary

The invention provides for a method of preparing an isolated serum fraction of platelet rich fibrin (PRF), comprising the steps of a. providing platelet rich plasma (PRP) without the addition of an anticoagulant; b. clotting the PRP to obtain a coagel of PRF; and c. separating the coagel to isolate the serum fraction which comprises an activated platelet releasate; and further provides for the isolated serum fraction obtained by such method, and its medical use.